

Michael J Boeckh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7917661/publications.pdf>

Version: 2024-02-01

175
papers

14,152
citations

22548

61
h-index

25230

113
g-index

183
all docs

183
docs citations

183
times ranked

14446
citing authors

#	ARTICLE	IF	CITATIONS
1	Cytomegalovirus Viremia and Clinical Outcomes in Kenyan Children Diagnosed With Human Immunodeficiency Virus (HIV) in Hospital. <i>Clinical Infectious Diseases</i> , 2022, 74, 1237-1246.	2.9	5
2	Phylogenomics of SARS-CoV-2 in Emergency Shelters for People Experiencing Homelessness. <i>Journal of Infectious Diseases</i> , 2022, , .	1.9	3
3	Convergent clonal selection of donor- and recipient-derived CMV-specific T cells in hematopoietic stem cell transplant patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	2
4	Novel factors to predict respiratory viral disease progression in allogeneic hematopoietic cell transplant recipients. <i>Bone Marrow Transplantation</i> , 2022, 57, 649-657.	1.3	5
5	Pathogen-Specific Humoral Immunity and Infections in B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy Recipients with Multiple Myeloma. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 304.e1-304.e9.	0.6	12
6	Correlation of initial upper respiratory tract viral burden with progression to lower tract disease in adult allogeneic hematopoietic cell transplant recipients. <i>Journal of Clinical Virology</i> , 2022, 150-151, 105152.	1.6	5
7	Structure, receptor recognition, and antigenicity of the human coronavirus CCoV-HuPn-2018 spike glycoprotein. <i>Cell</i> , 2022, 185, 2279-2291.e17.	13.5	25
8	Role of Human Bocavirus Respiratory Tract Infection in Hematopoietic Cell Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2021, 73, e4392-e4399.	2.9	5
9	Donor-Derived CD4+ T Cells and Human Herpesvirus 6B Detection After Allogeneic Hematopoietic Cell Transplantation. <i>Journal of Infectious Diseases</i> , 2021, 223, 709-713.	1.9	4
10	Pulmonary Complications of Pediatric Hematopoietic Cell Transplantation. A National Institutes of Health Workshop Summary. <i>Annals of the American Thoracic Society</i> , 2021, 18, 381-394.	1.5	26
11	American Society of Transplantation and Cellular Therapy Series, 2: Management and Prevention of Aspergillosis in Hematopoietic Cell Transplantation Recipients. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 201-211.	0.6	23
12	American Society for Transplantation and Cellular Therapy Infectious Disease Guidelines: Preface to the Series. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 103-104.	0.6	6
13	CMV viral load kinetics as surrogate endpoints after allogeneic transplantation. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	35
14	Association between live childhood vaccines and COVID-19 outcomes: a national-level analysis. <i>Epidemiology and Infection</i> , 2021, 149, e75.	1.0	13
15	A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipients. <i>EClinicalMedicine</i> , 2021, 33, 100787.	3.2	14
16	Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation. <i>Blood</i> , 2021, 138, 34-43.	0.6	71
17	Antibodies to vaccine-preventable infections after CAR-T-cell therapy for B-cell malignancies. <i>JCI Insight</i> , 2021, 6, .	2.3	18
18	Risk factors for seasonal human coronavirus lower respiratory tract infection after hematopoietic cell transplantation. <i>Blood Advances</i> , 2021, 5, 1903-1914.	2.5	6

#	ARTICLE	IF	CITATIONS
19	Evaluating Specimen Quality and Results from a Community-Wide, Home-Based Respiratory Surveillance Study. <i>Journal of Clinical Microbiology</i> , 2021, 59, .	1.8	17
20	A human coronavirus evolves antigenically to escape antibody immunity. <i>PLoS Pathogens</i> , 2021, 17, e1009453.	2.1	183
21	Viral genomes reveal patterns of the SARS-CoV-2 outbreak in Washington State. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	58
22	A remote household-based approach to influenza self-testing and antiviral treatment. <i>Influenza and Other Respiratory Viruses</i> , 2021, 15, 469-477.	1.5	7
23	Comparison of Symptoms and RNA Levels in Children and Adults With SARS-CoV-2 Infection in the Community Setting. <i>JAMA Pediatrics</i> , 2021, 175, e212025.	3.3	80
24	Home Spirometry Telemonitoring for Early Detection of Bronchiolitis Obliterans Syndrome in Patients with Chronic Graft-versus-Host Disease. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 616.e1-616.e6.	0.6	20
25	Delayed-onset cytomegalovirus infection is frequent after discontinuing letermovir in cord blood transplant recipients. <i>Blood Advances</i> , 2021, 5, 3113-3119.	2.5	24
26	Outcomes of Hematopoietic Cell Transplantation in Patients with Mixed Response to Pretransplantation Treatment of Confirmed or Suspected Invasive Fungal Infection. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 684.e1-684.e9.	0.6	2
27	American Society for Transplantation and Cellular Therapy Series: #3 "Prevention of Cytomegalovirus Infection and Disease After Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 707-719.	0.6	45
28	Association of Inherited Chromosomally Integrated Human Herpesvirus 6 with Neurologic Symptoms and Management after Allogeneic Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 795.e1-795.e8.	0.6	4
29	Remote Household Observation for Noninfluenza Respiratory Viral Illness. <i>Clinical Infectious Diseases</i> , 2021, 73, e4411-e4418.	2.9	17
30	Human parainfluenza virus evolution during lung infection of immunocompromised individuals promotes viral persistence. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	12
31	Mathematical Modeling of Within-Host, Untreated, Cytomegalovirus Infection Dynamics after Allogeneic Transplantation. <i>Viruses</i> , 2021, 13, 2292.	1.5	4
32	Inflammatory Cytokine Profile in Individuals with Inherited Chromosomally Integrated Human Herpesvirus 6. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 254-261.	2.0	7
33	A Phase 2b, Randomized, Double-blind, Placebo-Controlled Multicenter Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of Presatovir in Hematopoietic Cell Transplant Recipients with Respiratory Syncytial Virus Infection of the Lower Respiratory Tract. <i>Clinical Infectious Diseases</i> , 2020, 71, 2787-2795.	2.9	44
34	Cytomegalovirus Humoral Response Against Epithelial Cell Entry-Mediated Infection in the Primary Infection Setting After Hematopoietic Cell Transplantation. <i>Journal of Infectious Diseases</i> , 2020, 221, 1470-1479.	1.9	3
35	A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial of Presatovir for the Treatment of Respiratory Syncytial Virus Upper Respiratory Tract Infection in Hematopoietic-Cell Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2020, 71, 2777-2786.	2.9	53
36	The Seattle Flu Study: a multiarm community-based prospective study protocol for assessing influenza prevalence, transmission and genomic epidemiology. <i>BMJ Open</i> , 2020, 10, e037295.	0.8	25

#	ARTICLE	IF	CITATIONS
37	Cryptic transmission of SARS-CoV-2 in Washington state. <i>Science</i> , 2020, 370, 571-575.	6.0	217
38	Immunogenicity of Inactivated Varicella Zoster Vaccine in Autologous Hematopoietic Stem Cell Transplant Recipients and Patients With Solid or Hematologic Cancer. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa172.	0.4	6
39	Point-of-care molecular testing and antiviral treatment of influenza in residents of homeless shelters in Seattle, WA: study protocol for a stepped-wedge cluster-randomized controlled trial. <i>Trials</i> , 2020, 21, 956.	0.7	7
40	Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation. <i>Immunity</i> , 2020, 53, 98-105.e5.	6.6	376
41	Late infectious complications in hematopoietic cell transplantation survivors: a population-based study. <i>Blood Advances</i> , 2020, 4, 1232-1241.	2.5	16
42	Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1378.	3.8	103
43	Risk Factors for Parainfluenza Virus Lower Respiratory Tract Disease after Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 163-171.	2.0	25
44	Survival outcomes of allogeneic hematopoietic cell transplants with EBV-positive or EBV-negative post-transplant lymphoproliferative disorder, A CIBMTR study. <i>Transplant Infectious Disease</i> , 2019, 21, e13145.	0.7	22
45	Respiratory Viral Infections in Transplant Recipients. , 2019, , 679-695.		0
46	Human cytomegalovirus seropositivity is associated with decreased survival in glioblastoma patients. <i>Neuro-Oncology Advances</i> , 2019, 1, vdz020.	0.4	14
47	Human Herpesvirus 6B and Lower Respiratory Tract Disease After Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2019, 37, 2670-2681.	0.8	20
48	Prospective Assessment of Cytomegalovirus Immunity in High-Risk Donor-Seropositive/Recipient-Seronegative Liver Transplant Recipients Receiving Either Preemptive Therapy or Antiviral Prophylaxis. <i>Journal of Infectious Diseases</i> , 2019, 220, 752-760.	1.9	27
49	Evaluating addition of self-collected throat swabs to nasal swabs for respiratory virus detection. <i>Journal of Clinical Virology</i> , 2019, 115, 43-46.	1.6	12
50	Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapy. <i>Blood Advances</i> , 2019, 3, 3590-3601.	2.5	52
51	Human Rhinovirus Infections in Hematopoietic Cell Transplant Recipients: Risk Score for Progression to Lower Respiratory Tract Infection. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1011-1021.	2.0	29
52	RNA Sequencing of the <i>In Vivo</i> Human Herpesvirus 6B Transcriptome To Identify Targets for Clinical Assays Distinguishing between Latent and Active Infections. <i>Journal of Virology</i> , 2019, 93, .	1.5	16
53	A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Oral Brincidofovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 369-381.	2.0	151
54	Characteristics and Outcomes of Coronavirus Infection in Children: The Role of Viral Factors and an Immunocompromised State. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2019, 8, 21-28.	0.6	135

#	ARTICLE	IF	CITATIONS
55	Freesia Study Design: JNJ-53718678 in Hematopoietic Cell Transplant Recipients with Respiratory Syncytial Virus Infection of the Upper Respiratory Tract. <i>Blood</i> , 2019, 134, 4478-4478.	0.6	1
56	Mapping person-to-person variation in viral mutations that escape polyclonal serum targeting influenza hemagglutinin. <i>ELife</i> , 2019, 8, .	2.8	80
57	High Incidence of Herpes Zoster after Cord Blood Hematopoietic Cell Transplant Despite Longer Duration of Antiviral Prophylaxis. <i>Blood</i> , 2019, 134, 4556-4556.	0.6	0
58	Alveolar levels of immuno-inflammatory mediators in diffuse alveolar hemorrhage after allogeneic transplant. <i>Bone Marrow Transplantation</i> , 2018, 53, 1206-1209.	1.3	3
59	Human Herpesvirus-6B Reactivation Is a Risk Factor for Grades II to IV Acute Graft-versus-Host Disease after Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2324-2336.	2.0	51
60	Viral Kinetic Correlates of Cytomegalovirus Disease and Death after Hematopoietic Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S20.	2.0	4
61	Use of Viral Load as a Surrogate Marker in Clinical Studies of Cytomegalovirus in Solid Organ Transplantation: A Systematic Review and Meta-analysis. <i>Clinical Infectious Diseases</i> , 2018, 66, 617-631.	2.9	67
62	Diagnostic and Prognostic Plasma Biomarkers for Idiopathic Pneumonia Syndrome after Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 678-686.	2.0	18
63	Graft-Derived Reconstitution of Mucosal-Associated Invariant T Cells after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 242-251.	2.0	70
64	Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. <i>Blood</i> , 2018, 131, 121-130.	0.6	374
65	871. Symptomatic Respiratory Syncytial Virus and Adenovirus Upper Respiratory Tract Infections Increase the Risk of Invasive Aspergillosis After Allogeneic Hematopoietic Cell Transplantation. <i>Open Forum Infectious Diseases</i> , 2018, 5, S24-S25.	0.4	4
66	1560. Clinical Presentation of BK Virus-Associated Hemorrhagic Cystitis (HC) After Hematopoietic Cell Transplantation (HCT). <i>Open Forum Infectious Diseases</i> , 2018, 5, S485-S486.	0.4	0
67	750. Respiratory Virus Infections and Airflow Obstruction After Allogeneic Hematopoietic Cell Transplantation. <i>Open Forum Infectious Diseases</i> , 2018, 5, S269-S270.	0.4	0
68	Antibiotic Exposure Prior to Respiratory Viral Infection Is Associated with Progression to Lower Respiratory Tract Disease in Allogeneic Hematopoietic Cell Transplant Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2293-2301.	2.0	25
69	A Modified Intensive Strategy to Prevent Cytomegalovirus Disease in Seropositive Umbilical Cord Blood Transplantation Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2094-2100.	2.0	23
70	Initial High Viral Load Is Associated with Prolonged Shedding of Human Rhinovirus in Allogeneic Hematopoietic Cell Transplant Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2160-2163.	2.0	19
71	Reply to Author. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2166.	2.0	0
72	Comparative genomic, transcriptomic, and proteomic reannotation of human herpesvirus 6. <i>BMC Genomics</i> , 2018, 19, 204.	1.2	45

#	ARTICLE	IF	CITATIONS
73	The cumulative burden of double-stranded DNA virus detection after allogeneic HCT is associated with increased mortality. <i>Blood</i> , 2017, 129, 2316-2325.	0.6	126
74	Validation of single nucleotide polymorphisms in invasive aspergillosis following hematopoietic cell transplantation. <i>Blood</i> , 2017, 129, 2693-2701.	0.6	80
75	Human rhinovirus detection in the lower respiratory tract of hematopoietic cell transplant recipients: association with mortality. <i>Haematologica</i> , 2017, 102, 1120-1130.	1.7	68
76	Outcomes of hematopoietic cell transplantation using donors or recipients with inherited chromosomally integrated HHV-6. <i>Blood</i> , 2017, 130, 1062-1069.	0.6	65
77	Clinical Significance of Human Coronavirus in Bronchoalveolar Lavage Samples From Hematopoietic Cell Transplant Recipients and Patients With Hematologic Malignancies. <i>Clinical Infectious Diseases</i> , 2017, 64, 1532-1539.	2.9	65
78	Cytomegalovirus (CMV) DNA Quantitation in Bronchoalveolar Lavage Fluid From Hematopoietic Stem Cell Transplant Recipients With CMV Pneumonia. <i>Journal of Infectious Diseases</i> , 2017, 215, 1514-1522.	1.9	63
79	Herpes Zoster in Autologous Hematopoietic Cell Transplant Recipients in the Era of Acyclovir or Valacyclovir Prophylaxis and Novel Treatment and Maintenance Therapies. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 505-511.	2.0	35
80	Adoptive Immunotherapy of Viral Infections: Should Infectious Disease Embrace Cellular Immunotherapy?. <i>Journal of Infectious Diseases</i> , 2017, 216, 926-928.	1.9	8
81	Prolonged Shedding of Human Coronavirus in Hematopoietic Cell Transplant Recipients: Risk Factors and Viral Genome Evolution. <i>Journal of Infectious Diseases</i> , 2017, 216, 203-209.	1.9	64
82	Supplemental Oxygen-Free Days in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus. <i>Journal of Infectious Diseases</i> , 2017, 216, 1235-1244.	1.9	18
83	Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation. <i>New England Journal of Medicine</i> , 2017, 377, 2433-2444.	13.9	796
84	Comparison of self-collected nasal swabs with oral washes for sequential viral load monitoring in lung transplant recipients with respiratory virus infection. <i>Journal of Clinical Virology</i> , 2017, 91, 49-51.	1.6	2
85	Maternal Highly Active Antiretroviral Therapy Reduces Vertical Cytomegalovirus Transmission But Does Not Reduce Breast Milk Cytomegalovirus Levels. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 332-338.	0.5	8
86	Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials: Table 1.. <i>Clinical Infectious Diseases</i> , 2017, 64, 87-91.	2.9	686
87	Parallel evolution of influenza across multiple spatiotemporal scales. <i>ELife</i> , 2017, 6, .	2.8	112
88	A Prospective Study Comparing Self-Collected Nasal Swabs to Oral Washes for Monitoring Viral Load Kinetics in Lung Transplant Recipients With Respiratory Virus Infection. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	1
89	Correlation between HSV-1 Recipient Serostatus And Increased Mortality In A Large Single Center Cohort Of Allogeneic Hematopoietic Cell Transplant (HCT) Recipients. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	0
90	Kinetic Features of Double Stranded DNA Virus Detection after Allogeneic Hematopoietic Cell Transplantation. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	0

#	ARTICLE	IF	CITATIONS
91	Oxygen-Free Days and Mortality Among Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus (RSV) Infection. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	0
92	Clinical Significance of Human Coronavirus in Bronchoalveolar Lavage Samples From Hematopoietic Cell Transplantation Recipients and Hematologic Malignancy Patients. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	0
93	AABB Committee Report: reducing transfusion-transmitted cytomegalovirus infections. <i>Transfusion</i> , 2016, 56, 1581-1587.	0.8	33
94	Replication of associations between genetic polymorphisms and chronic graft-versus-host disease. <i>Blood</i> , 2016, 128, 2450-2456.	0.6	32
95	Human Metapneumovirus Infections Following Hematopoietic Cell Transplantation: Factors Associated With Disease Progression. <i>Clinical Infectious Diseases</i> , 2016, 63, 178-185.	2.9	43
96	Search continues for a CMV vaccine for transplant recipients. <i>Lancet Haematology</i> , the, 2016, 3, e58-e59.	2.2	3
97	Correlation and Agreement of Handheld Spirometry with Laboratory Spirometry in Allogeneic Hematopoietic Cell Transplant Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 925-931.	2.0	31
98	Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. <i>Blood</i> , 2016, 127, 2427-2438.	0.6	403
99	How I treat respiratory viral infections in the setting of intensive chemotherapy or hematopoietic cell transplantation. <i>Blood</i> , 2016, 127, 2682-2692.	0.6	77
100	Decline in the Use of Surgical Biopsy for Diagnosis of Pulmonary Disease in Hematopoietic Cell Transplantation Recipients in an Era of Improved Diagnostics and Empirical Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2243-2249.	2.0	20
101	Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1636-1645.	2.0	71
102	Rhinovirus, Coronavirus, Enterovirus, and Bocavirus After Hematopoietic Cell Transplantation or Solid Organ Transplantation. , 2016, , 599-608.		1
103	Genetic risk factors for sclerotic graft-versus-host disease. <i>Blood</i> , 2016, 128, 1516-1524.	0.6	18
104	A multicenter, longitudinal, interventional, double blind randomized clinical trial in hematopoietic cell transplant recipients residing in remote areas: Lessons learned from the late cytomegalovirus prevention trial. <i>Contemporary Clinical Trials Communications</i> , 2016, 4, 84-89.	0.5	2
105	Symptomatic Respiratory Virus Infection and Chronic Lung Allograft Dysfunction. <i>Clinical Infectious Diseases</i> , 2016, 62, 313-319.	2.9	92
106	Detection of Human Herpesvirus 6B (HHV-6B) Reactivation in Hematopoietic Cell Transplant Recipients with Inherited Chromosomally Integrated HHV-6A by Droplet Digital PCR. <i>Journal of Clinical Microbiology</i> , 2016, 54, 1223-1227.	1.8	39
107	In vitro studies of the impact of maribavir on CMV-specific cellular immune responses. <i>Journal of Clinical Virology</i> , 2016, 75, 53-59.	1.6	9
108	Efficient identification of inherited chromosomally integrated human herpesvirus 6 using specimen pooling. <i>Journal of Clinical Virology</i> , 2016, 77, 71-76.	1.6	20

#	ARTICLE	IF	CITATIONS
109	Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study. <i>Lancet Haematology</i> , 2016, 3, e119-e127.	2.2	307
110	Successful Treatment of Parainfluenza Virus Respiratory Tract Infection With DAS181 in 4 Immunocompromised Children. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2015, 4, 114-118.	0.6	45
111	Efficacy of transfusion with granulocytes from G-CSF/dexamethasone-treated donors in neutropenic patients with infection. <i>Blood</i> , 2015, 126, 2153-2161.	0.6	184
112	Clinical disease due to enterovirus D68 in adult hematologic malignancy patients and hematopoietic cell transplant recipients. <i>Blood</i> , 2015, 125, 1724-1729.	0.6	43
113	Idiopathic pneumonia syndrome after hematopoietic cell transplantation: evidence of occult infectious etiologies. <i>Blood</i> , 2015, 125, 3789-3797.	0.6	137
114	Valganciclovir for the Prevention of Complications of Late Cytomegalovirus Infection After Allogeneic Hematopoietic Cell Transplantation. <i>Annals of Internal Medicine</i> , 2015, 162, 1-10.	2.0	322
115	Reprint of: Recent Advances in Cytomegalovirus: An Update on Pharmacologic and Cellular Therapies. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S19-S24.	2.0	26
116	Reevaluation of the Pretransplant Assessment of Mortality Score after Allogeneic Hematopoietic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 848-854.	2.0	40
117	A patient self-collection method for longitudinal monitoring of respiratory virus infection in solid organ transplant recipients. <i>Journal of Clinical Virology</i> , 2015, 62, 98-102.	1.6	7
118	Effectiveness and safety of lower dose prednisone for initial treatment of acute graft-versus-host disease: a randomized controlled trial. <i>Haematologica</i> , 2015, 100, 842-848.	1.7	75
119	Reduced Mortality of Cytomegalovirus Pneumonia After Hematopoietic Cell Transplantation Due to Antiviral Therapy and Changes in Transplantation Practices. <i>Clinical Infectious Diseases</i> , 2015, 61, 31-39.	2.9	114
120	Clinical Outcomes Associated With Respiratory Virus Detection Before Allogeneic Hematopoietic Stem Cell Transplant. <i>Clinical Infectious Diseases</i> , 2015, 61, 192-202.	2.9	112
121	Recent Advances in Cytomegalovirus: An Update on Pharmacologic and Cellular Therapies. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 24-29.	2.0	87
122	Prevalence of Chromosomally Integrated Human Herpesvirus 6 in Patients with Human Herpesvirus 6 Central Nervous System Dysfunction. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 371-373.	2.0	22
123	Biomarkers for Idiopathic Pneumonia Syndrome after Hematopoietic Cell Transplantation: Comparison with Viral Infectious Pneumonia. <i>Blood</i> , 2015, 126, 1927-1927.	0.6	0
124	Detection of Multiple Double-Stranded DNA Viruses after Cord Blood Transplantation Is Frequent and Persistent. <i>Blood</i> , 2015, 126, 3104-3104.	0.6	1
125	Maternal Valacyclovir and Infant Cytomegalovirus Acquisition: A Randomized Controlled Trial among HIV-Infected Women. <i>PLoS ONE</i> , 2014, 9, e87855.	1.1	40
126	Co-Reactivation of Human Herpesvirus 6 (HHV-6) and Cytomegalovirus (CMV) is Associated with Worse Clinical Outcome in Critically Ill Immunocompetent Adults. <i>Open Forum Infectious Diseases</i> , 2014, 1, S43-S43.	0.4	0

#	ARTICLE	IF	CITATIONS
127	601Antibiotic Use Patterns Early After Hematopoietic Cell Transplantation (HCT) Influence the Risk of Viral Infections and Acute Graft-Versus-Host Disease (GVHD). <i>Open Forum Infectious Diseases</i> , 2014, 1, S26-S26.	0.4	0
128	Respiratory Syncytial Virus in Hematopoietic Cell Transplant Recipients: Factors Determining Progression to Lower Respiratory Tract Disease. <i>Journal of Infectious Diseases</i> , 2014, 209, 1195-1204.	1.9	119
129	Nosocomial Transmission of Respiratory Syncytial Virus in an Outpatient Cancer Center. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 844-851.	2.0	33
130	Identification of Chromosomally Integrated Human Herpesvirus 6 by Droplet Digital PCR. <i>Clinical Chemistry</i> , 2014, 60, 765-772.	1.5	114
131	Management of Respiratory Viral Infections in Hematopoietic Cell Transplant Recipients and Patients With Hematologic Malignancies. <i>Clinical Infectious Diseases</i> , 2014, 59, S344-S351.	2.9	172
132	Human herpesvirus 6 can be detected in cerebrospinal fluid without associated symptoms after allogeneic hematopoietic cell transplantation. <i>Journal of Clinical Virology</i> , 2014, 61, 289-292.	1.6	34
133	Parainfluenza Virus Lower Respiratory Tract Disease After Hematopoietic Cell Transplant: Viral Detection in the Lung Predicts Outcome. <i>Clinical Infectious Diseases</i> , 2014, 58, 1357-1368.	2.9	113
134	Pharmacokinetic and Pharmacodynamic Analysis of Inosine Monophosphate Dehydrogenase Activity in Hematopoietic Cell Transplantation Recipients Treated with Mycophenolate Mofetil. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1121-1129.	2.0	21
135	Recipient Pretransplant Inosine Monophosphate Dehydrogenase Activity in Nonmyeloablative Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1544-1552.	2.0	7
136	Combination Therapy with Amantadine, Oseltamivir and Ribavirin for Influenza a Infection: Safety and Pharmacokinetics. <i>Antiviral Therapy</i> , 2013, 18, 377-386.	0.6	61
137	Mortality Rates of Human Metapneumovirus and Respiratory Syncytial Virus Lower Respiratory Tract Infections in Hematopoietic Cell Transplantation Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1220-1226.	2.0	122
138	Outcome of Respiratory Syncytial Virus Lower Respiratory Tract Disease in Hematopoietic Cell Transplant Recipients Receiving Aerosolized Ribavirin: Significance of Stem Cell Source and Oxygen Requirement. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 589-596.	2.0	70
139	The Serum Galactomannan Index Predicts Mortality in Hematopoietic Stem Cell Transplant Recipients With Invasive Aspergillosis. <i>Clinical Infectious Diseases</i> , 2013, 57, 1001-1004.	2.9	63
140	Nonrelapse Mortality and Mycophenolic Acid Exposure in Nonmyeloablative Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1159-1166.	2.0	29
141	Fourth European Conference on Infections in Leukaemia (ECIL-4): Guidelines for Diagnosis and Treatment of Human Respiratory Syncytial Virus, Parainfluenza Virus, Metapneumovirus, Rhinovirus, and Coronavirus. <i>Clinical Infectious Diseases</i> , 2013, 56, 258-266.	2.9	279
142	Self-Collection of Foam Nasal Swabs for Respiratory Virus Detection by PCR among Immunocompetent Subjects and Hematopoietic Cell Transplant Recipients. <i>Journal of Clinical Microbiology</i> , 2013, 51, 324-327.	1.8	24
143	Respiratory Syncytial Virus Lower Respiratory Disease in Hematopoietic Cell Transplant Recipients: Viral RNA Detection in Blood, Antiviral Treatment, and Clinical Outcomes. <i>Clinical Infectious Diseases</i> , 2013, 57, 1731-1741.	2.9	111
144	Influenza Viral RNA Detection in Blood as a Marker to Predict Disease Severity in Hematopoietic Cell Transplant Recipients. <i>Journal of Infectious Diseases</i> , 2012, 206, 1872-1877.	1.9	42

#	ARTICLE	IF	CITATIONS
145	A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Infectious Diseases</i> , 2012, 12, 290-299.	4.6	224
146	Neutropenic Diet – Good Practice or Myth?. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1318-1319.	2.0	14
147	Impact of Corticosteroid Treatment and Antiviral Therapy on Clinical Outcomes in Hematopoietic Cell Transplant Patients Infected with Influenza Virus. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 979-986.	2.0	58
148	Differences in clinical outcomes after 2009 influenza A/H1N1 and seasonal influenza among hematopoietic cell transplant recipients. <i>Blood</i> , 2011, 117, 5050-5056.	0.6	129
149	Intensive strategy to prevent CMV disease in seropositive umbilical cord blood transplant recipients. <i>Blood</i> , 2011, 118, 5689-5696.	0.6	94
150	H275Y Mutant Pandemic (H1N1) 2009 Virus in Immunocompromised Patients. <i>Emerging Infectious Diseases</i> , 2011, 17, 653-660.	2.0	48
151	Complications, Diagnosis, Management, and Prevention of CMV Infections: Current and Future. <i>Hematology American Society of Hematology Education Program</i> , 2011, 2011, 305-309.	0.9	75
152	Cytomegalovirus: pathogen, paradigm, and puzzle. <i>Journal of Clinical Investigation</i> , 2011, 121, 1673-1680.	3.9	293
153	Human rhinovirus and coronavirus detection among allogeneic hematopoietic stem cell transplantation recipients. <i>Blood</i> , 2010, 115, 2088-2094.	0.6	161
154	How I treat influenza in patients with hematologic malignancies. <i>Blood</i> , 2010, 115, 1331-1342.	0.6	109
155	Timing and severity of community acquired respiratory virus infections after myeloablative versus non-myeloablative hematopoietic stem cell transplantation. <i>Haematologica</i> , 2009, 94, 1101-1108.	1.7	86
156	The Contribution of Malglycemia to Mortality among Allogeneic Hematopoietic Cell Transplant Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 344-351.	2.0	80
157	How we treat cytomegalovirus in hematopoietic cell transplant recipients. <i>Blood</i> , 2009, 113, 5711-5719.	0.6	495
158	The challenge of respiratory virus infections in hematopoietic cell transplant recipients. <i>British Journal of Haematology</i> , 2008, 143, 455-467.	1.2	131
159	Randomized Controlled Multicenter Trial of Aerosolized Ribavirin for Respiratory Syncytial Virus Upper Respiratory Tract Infection in Hematopoietic Cell Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2007, 44, 245-249.	2.9	181
160	Community Respiratory Virus Infections in Immunocompromised Patients: Hematopoietic Stem Cell and Solid Organ Transplant Recipients, and Individuals with Human Immunodeficiency Virus Infection. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2007, 28, 222-242.	0.8	183
161	Brief Communication: Fatal Human Metapneumovirus Infection in Stem-Cell Transplant Recipients. <i>Annals of Internal Medicine</i> , 2006, 144, 344.	2.0	225
162	Airflow Decline after Myeloablative Allogeneic Hematopoietic Cell Transplantation: The Role of Community Respiratory Viruses. <i>Journal of Infectious Diseases</i> , 2006, 193, 1619-1625.	1.9	168

#	ARTICLE	IF	CITATIONS
163	Rising CMV PP65 antigenemia and DNA levels during preemptive antiviral therapy. <i>Haematologica</i> , 2005, 90, 439.	1.7	3
164	Influenza Infections after Hematopoietic Stem Cell Transplantation: Risk Factors, Mortality, and the Effect of Antiviral Therapy. <i>Clinical Infectious Diseases</i> , 2004, 39, 1300-1306.	2.9	345
165	Pretransplantation Respiratory Syncytial Virus Infection: Impact of a Strategy to Delay Transplantation. <i>Clinical Infectious Diseases</i> , 2004, 39, 673-680.	2.9	69
166	Immunologic recovery after hematopoietic cell transplantation with nonmyeloablative conditioning. <i>Experimental Hematology</i> , 2003, 31, 941-952.	0.2	96
167	Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. <i>Blood</i> , 2003, 101, 407-414.	0.6	554
168	Rhinovirus Infections in Hematopoietic Stem Cell Transplant Recipients with Pneumonia. <i>Clinical Infectious Diseases</i> , 2003, 36, 1139-1143.	2.9	129
169	Factors affecting antibody levels after allogeneic hematopoietic cell transplantation. <i>Blood</i> , 2003, 101, 3319-3324.	0.6	55
170	Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation. <i>Blood</i> , 2003, 102, 3060-3067.	0.6	225
171	Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2003, 102, 2777-2785.	0.6	249
172	Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome. <i>Blood</i> , 2001, 98, 573-578.	0.6	284
173	Neutropenia in Allogeneic Marrow Transplant Recipients Receiving Ganciclovir for Prevention of Cytomegalovirus Disease: Risk Factors and Outcome. <i>Blood</i> , 1997, 90, 2502-2508.	0.6	205
174	IDIOPATHIC PNEUMONIA SYNDROME. <i>Transplantation</i> , 1997, 63, 1079-1086.	0.5	200
175	Cyclosporine or Cyclosporine Plus Methylprednisolone for Prophylaxis of Graft-Versus-Host Disease: A Prospective, Randomized Trial. <i>Blood</i> , 1997, 89, 3880-3887.	0.6	3